इसराइल -
हिब्रू -
Ministry of Health
ריבסטיגמין דקסל 1.5 מג
dexcel ltd, israel - rivastigmine as hydrogen tartrate - קפסולה קשיחה - rivastigmine as hydrogen tartrate 1.5 mg - rivastigmine
इसराइल -
हिब्रू -
Ministry of Health
ריבסטיגמין דקסל 3 מג
dexcel ltd, israel - rivastigmine as hydrogen tartrate - קפסולה קשיחה - rivastigmine as hydrogen tartrate 3 mg - rivastigmine
इसराइल -
हिब्रू -
Ministry of Health
ריבסטיגמין דקסל 4.5 מג
dexcel ltd, israel - rivastigmine as hydrogen tartrate - קפסולה קשיחה - rivastigmine as hydrogen tartrate 4.5 mg - rivastigmine
इसराइल -
हिब्रू -
Ministry of Health
ריבסטיגמין דקסל 6 מג
dexcel ltd, israel - rivastigmine as hydrogen tartrate - קפסולה קשיחה - rivastigmine as hydrogen tartrate 6 mg - rivastigmine
इसराइल -
हिब्रू -
Ministry of Health
אמנדין 100
megapharm ltd - amantadine hemisulfate - טבליות מצופות פילם - amantadine hemisulfate 100 mg - amantadine
इसराइल -
हिब्रू -
Ministry of Health
אמנדין 100
megapharm ltd - amantadine hemisulfate - טבליות מצופות פילם - amantadine hemisulfate 100 mg - amantadine
इसराइल -
हिब्रू -
Ministry of Health
טרקליר 62.5 מג
j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 62.5 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease
इसराइल -
हिब्रू -
Ministry of Health
טרקליר 125 מג
j-c health care ltd - bosentan - טבליות מצופות פילם - bosentan 125 mg - bosentan - bosentan - treatment of pulmonary arterial hypertension (pah) in patients of who functional class ii-iv.reduction in the number of new digital ulcers in patients with systemic sclerosis with active digital ulcer disease
इसराइल -
हिब्रू -
Ministry of Health
דטסקאן
eldan electronic instruments co ltd - ioflupane - תמיסה להזרקה - ioflupane 74 mbq/ml - iodine ioflupane (123i) - other dopaminergic agents - datscan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum: - of patients with clinically uncertain parkinsonian syndromes in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson's disease multiple system atrophy and progressive supranuclear palsy. - datscan is unable to discriminate between parkinson's disease multiple system atrophy and progressive supranuclear palsy. - to help differentiate probable dementia with lewy bodies from alzheimer's disease. datscan is unable to discriminate between dementia with lewy bodies and parkinson's disease dementia